Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells

Inclusion Criteria: 1. Histologically confirmed recurrent or metastatic cancer 2. Measurable disease 3. Progressed after all standard treatment 4. ECOG performance status of 0 to 2 5. Expected life span ≥ 3 months 6. Toxicities from prior treatment has resolved. Washout period is 4 weeks for chemotherapy, and 2 weeks for targeted therapy 7. Major organs function normally 8. Women at pregnant ages should be under contraception 9. Willing and able to provide informed consent Exclusion Criteria: 1. Other malignancy within 5 years prior to entry into the study, expect for treated non melanoma skin cancer and cervical carcinoma in situ 2. Poor vasculature 3. Disease to the central nervous system 4. Blood-borne infectious disease, eg. hepatitis B 5. History of mandatory custody because of psychosis or other psychological disease inappropriate for treatment deemed by treating physician 6. With other immune diseases, or chronic use of immunosuppressants or steroids 7. Pregnancy (women of childbearing potential: Refusal or inability to use effective means of contraception) 8. Breastfeeding 9. Decision of unsuitableness by principal investigator or physician-in-charge